Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
RGD |
Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
|
17908994 |
2007 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Using data from The Cancer Genome Atlas, we found that Slug expression positively correlated with that of c-Jun and cyclin D1 in human prostate cancers.
|
27385093 |
2016 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer.
|
10884916 |
2000 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Expression of miR-124, STAT3, p-STAT3, Bcl-2 and Cyclin D1 was compared between normal human prostate epithelial cell RWPE-1 and prostate cancer cell DU145.
|
28617558 |
2017 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
SGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1.
|
24739041 |
2014 |
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We tested whether genetic variations within the CCND1 gene are related to clinical outcomes in prostate cancer patients receiving radical prostatectomy.
|
23354566 |
2013 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers.
|
9873247 |
1998 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Collectively, our findings suggest that the hormone-mediated recruitment of cyclin D1 to sites of DDR may facilitate the resistance of prostate cancer cells to DNA damage therapies and highlight the need to explore other therapeutic approaches in prostate cancer to prevent or overcome drug resistance.
|
26582866 |
2016 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, deregulation of CCND1 may be a major cause of cisplatin resistance in testicular germ cell tumors and may also be implicated in ovarian and prostate cancers.
|
20395447 |
2010 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These data demonstrate that differential cyclin D1 status may influence clinicopathological parameters, and reveal new insight as to the regulation and potential consequence of cyclin D1 expression in prostate cancer.
|
17375037 |
2007 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Meanwhile, the expression level of CCND1 was significantly upregulated in the PCa tissues and cell lines, which presented negative correlation with the expression of miR-487a-3p.
|
31309555 |
2020 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
As a result, the CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I axis was identified as a bottleneck in the miRNA-mediated gene expression regulatory network of PCa according to network topological analysis.
|
29467540 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Concomitantly, BBP treatment decreased the protein levels of phosphorylated retinoblastoma, cyclin D1 and E, cyclin-dependent kinase (CDK) 4 and 2, and pre-replication complex (CDC6 and MCM7) in LNCaP and PC-3 cells, whereas CDK inhibitor p27 was elevated in these cell lines.
|
22067725 |
2012 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, these data establish the potency of cyclin D1 as an AR corepressor and provide support for additional studies examining the efficacy of developing novel prostate cancer therapies for both androgen-dependent and -independent tumors.
|
12941814 |
2003 |
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
However, the AA genotype of CCND1 showed a tendency to increase prostate cancer risk in subjects aged 70 years or older (odds ratio [OR] = 2.14, 95% confidence interval [CI] = 0.86-5.27, p = 0.096).
|
14981950 |
2004 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression.
|
17804732 |
2007 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Long noncoding RNA LOXL1-AS1 regulates prostate cancer cell proliferation and cell cycle progression through miR-541-3p and CCND1.
|
30278884 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism.
|
12455063 |
2003 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This study provides a molecular basis to support the correlation of IL-8 expression with that of cyclin D1 in human prostate cancer and suggests a mechanism by which this chemokine promotes cell proliferation.
|
17606477 |
2007 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, results present that SNHG7 regulates the cycle progression and acts as an oncogenic gene in the prostate cancer tumorigenesis via miR-503/Cyclin D1 pathway, revealing the vital role of lncRNA/miRNA/mRNA axis in prostate cancer carcinogenesis.
|
29571017 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our results identify Sam68 as the first splicing factor to affect CCND1 alternative splicing in prostate cancer cells, and suggest that increased levels of Sam68 may stimulate cyclin D1b expression in human prostate cancers.
|
20028857 |
2010 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Prostate cancer was used as a paradigm because this tumor type is reliant at all stages of the disease on androgen receptor (AR) signaling, and cyclin D1 has been shown to negatively modulate AR-dependent expression of prostate-specific antigen (KLK3/PSA).
|
21212260 |
2011 |
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer.
|
19706803 |
2009 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
CTD_human |
This study provides a molecular basis to support the correlation of IL-8 expression with that of cyclin D1 in human prostate cancer and suggests a mechanism by which this chemokine promotes cell proliferation.
|
17606477 |
2007 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we investigated the diagnostic value of 3 different genes associated with CaP carcinogenesis, encoding for cell cycle (MDM2, CCND1) and apoptotic (Fas) genes that are differentially expressed in CaP.
|
20822933 |
2012 |